Cited by 150Advanced Drug Delivery SystemsParkinson's Disease Mechanisms and TreatmentsNanoparticle-Based Drug Delivery

Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease

Open access
Garbayo, E., Montero-Menei, C.N., Ansorena, E., Lanciego, J.L., Aymerich, M.S., Blanco-Prieto, M.J.·2009·Journal of Controlled Release

Abstract

Glial cell line-derived neurotrophic factor (GDNF) has shown promise in the treatment of neurodegenerative disorders of basal ganglia origin such us Parkinson's disease (PD). In this study, we investigated the neurorestorative effect of controlled GDNF delivery using biodegradable microspheres in an animal model with partial dopaminergic lesion. Microspheres were loaded with N-glycosylated recombinant GDNF and prepared using the Total Recirculation One-Machine System (TROMS). GDNF-loaded microparticles were unilaterally injected into the rat striatum by stereotaxic surgery two weeks after a unilateral partial 6-OHDA nigrostriatal lesion. Animals were tested for amphetamine-induced rotational asymmetry at different times and were sacrificed two months after microsphere implantation for immunohistochemical analysis. The putative presence of serum IgG antibodies against rat glycosylated GDNF was analyzed for addressing safety issues. The results demonstrated that GDNF-loaded microspheres, improved the rotational behavior induced by amphetamine of the GDNF-treated animals together with an increase in the density of TH positive fibers at the striatal level. The developed GDNF-loaded microparticles proved to be suitable to release biologically active GDNF over up to 5 weeks in vivo. Furthermore, none of the animals developed antibodies against GDNF demonstrating the safety of glycosylated GDNF use.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2008.12.010

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GDNF-loaded microsphere increased TH-positive fibers in striatum and substantia nigra, suggesting neuroprotection and neurorestoration activity.

    “Apart from this GDNF-loaded microsphere increase in TH-positive fibers in the striatum and substantia nigra, the results suggested neuroprotection and neurorestoration activity.129,130”
  • PLGA-MS-mediated GDNF release demonstrated antiparkinsonian effects, confirmed by improvement in amphetamine-induced rotational behavior test.

    “Similar results were also observed by Garbayo et al., where PLGA-MS-mediated GDNF release demonstrated antiparkinsonian effects, as confirmed by the improvement in the amphetamine-induced rotational behavior test.130”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Garbayo, E., Montero-Menei, C. N., Ansorena, E., Lanciego, J. L., Aymerich, M. S., & Blanco-Prieto, M. J.
Affiliations
  • Universidad de Navarra (ES)
  • Centro de Investigación Médica Aplicada (ES)
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2009-04
Volume
135
Issue
2
Pages
119-126
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2075997145
Cited by
150
References
29
Citations by year
2026: 4 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 13 · 2019: 5 · 2018: 9 · 2017: 9 · 2016: 15 · 2015: 18 · 2014: 10 · 2013: 14 · 2012: 13
FWCI
3.75
Type
journal article
Language
en
Open access
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
glial cell line-derived neurotrophic factor, Parkinson's disease, biodegradable microspheres, controlled drug delivery, 6-hydroxydopamine lesion, nigrostriatal degeneration, striatum, amphetamine-induced rotation, tyrosine hydroxylase, neurorestoration, immunogenicity
MeSH terms
Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Brain, Cell Differentiation, Corpus Striatum, Disease Models, Animal, Drug Carriers, Female, Glycosylation, Immunohistochemistry, Kinetics, Microspheres, Models, Neurological, Parkinson Disease, Particle Size, Polyglycolic Acid, Recombinant Proteins, Drug Delivery Systems, PC12 Cells, Rats, Sprague-Dawley, Fluorescent Antibody Technique, Indirect, Lactic Acid, Glial Cell Line-Derived Neurotrophic Factor, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review